SCHEMBL30310899

SCHEMBL30310899

N[C@@H](CCO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 3/20 0.67
▸ ECE1 P42892 7/20 0.62
▸ KDM4E B2RXH2 1/20 0.62
▸ MEN1 O00255 1/20 0.62
▸ LMNA P02545 1/20 0.62
▸ MPO P05164 1/20 0.62
▸ MAPT P10636 1/20 0.62
▸ TSHR P16473 1/20 0.62
▸ BLM P54132 1/20 0.62
▸ PMP22 Q01453 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ HIF1A Q16665 1/20 0.62
▸ ALOX15 P16050 1/20 0.61
▸ ERAP2 Q6P179 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29924981 0.91 ACE (0.67) ACEECE1KDM4EMEN1LMNA
SCHEMBL5583849 0.91 ACE (0.69) ACEECE1KDM4EMEN1LMNA
SCHEMBL5583846 0.91 ACE (0.69) ACEECE1KDM4EMEN1LMNA
SCHEMBL11855463 0.91 ACE (0.72) ACEECE1KDM4EMEN1LMNA
SCHEMBL5583839 0.91 ACE (0.72) ACEECE1KDM4EMEN1LMNA
SCHEMBL29701966 0.91 ACE (0.72) ACEECE1KDM4EMEN1LMNA
SCHEMBL9596908 0.91 ACE (0.72) ACEECE1KDM4EMEN1LMNA
SCHEMBL9596897 0.91 ACE (0.72) ACEECE1KDM4EMEN1LMNA
SCHEMBL3359705 0.91 ACE (0.72) ACEECE1KDM4EMEN1LMNA
SCHEMBL5612810 0.91 ACE (0.72) ACEECE1KDM4EMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-09-25 — — US claimed
CN-118632858-A Gastric inhibitory peptide receptor ligands 3B制药有限公司 2024-09-10 — — CN claimed
EP-4423110-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-09-04 — — EP claimed
WO-2023072971-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-05-04 — — WO claimed
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-09-25 — — US disclosed
CN-118632858-A Gastric inhibitory peptide receptor ligands 3B制药有限公司 2024-09-10 — — CN disclosed
EP-4423110-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-09-04 — — EP disclosed
WO-2023072971-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-05-04 — — WO disclosed
EP-4170347-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2023-04-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS GIPR, VIP, GRPR ACE 3951/4885ECE1 715/4885KDM4E 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback